Translational Medicine Lead, Precision Medicine, Early Clinical Development
Pfizer Inc.
Groton, Connecticut
Kelly A. Fader is a Clinical Biomarker Lead within the Precision Medicine, Early Clinical Development (ECD) department at Pfizer. Her role involves the development and implementation of the biomarker strategy in early-stage clinical trials for internal medicine targets. Prior to transitioning to ECD, she worked as a research scientist in Pfizer’s Drug Safety Research & Development department, identifying and validating novel safety biomarkers. Dr. Fader completed her Honours Bachelor of Science in Biomedical Toxicology at the University of Guelph in Ontario, Canada. She then earned a dual major PhD in Biochemistry & Molecular Biology and Environmental Toxicology from Michigan State University investigating the mechanistic role of the aryl hydrocarbon receptor (AhR) in non-alcoholic fatty liver disease and other metabolic disorders. Dr. Fader currently supports the ‘Biomarkers of Drug-Induced Nervous System Injury Work Package’ within the Innovative Medicines Initiative (IMI)’s Translational Safety Biomarker Pipeline (TransBioLine) project and has been a member of the Society of Toxicology (SOT) since 2013.